Translational: Basic scientific research with a focus on novel anti-inflammatory therapies (to circumvent side effects), novel anti-cancer treatments (to overcome resistance and side effects) and the development of advanced GR-tailored drug screening platforms.
Nuclear Receptor: Focus on GR, MR, PPAR and ERR as individual drug targets and crosstalk mechanisms. These NRs (signaling and transcriptional mechanisms) are studied in-depth on a biomolecular level.
Research: Combining dry and wet lab experiments to validate fundamental insights in biologically/clinically relevant settings. Expertise with cell-based anti-inflammatory drug screening platforms.
Currently, corticosteroids in the clinic are too often used with a “one-size-fits-all” rationale for the treatment/management of inflammatory diseases, metabolic disorders and cancer. Glucocorticoid receptor (GR) regulation and responses are far more complex than previously recognized. GR is not a “one-size-fits-all” type of target, but requires a tailored approach when it comes to drug discovery to meet the correct insight that GR is a receptor demonstrating a high degree of plasticity. Multiple GR conformations must exist, likely resulting in different anti-inflammatory (AI) profiles. Trying to achieve a selective GR-mediated activation of particular AI profiles may offer the potential for the development of safer and disease-tailored GR-targeting medicines.
To showcase the world-class scientific research of the Karolien De Bosscher Lab, you can discover their scientific papers in more detail
We are always on the lookout for highly motivated colleagues to join our team. If you are interested, please contact us.
The Karolien De Bosscher Lab can only thrive thanks to the dedication and commitment of its people, no matter what their function or seniority.
To stay up to date in rapidly developing fields, scientists regularly interact with (international) colleagues. Conferences and other (scientific) events are an excellent way to facilitate such a continent-spanning knowledge exchange.